deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT02910700

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA)

Sponsor: M.D. Anderson Cancer Center

Conditions Metastatic Malignant Neoplasm in the Brain Metastatic Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Melanoma
Interventions Binimetinib Dabrafenib Encorafenib Laboratory Biomarker Analysis Nivolumab Pharmacological Study Trametinib
Updated 32 times since 2017 Last updated: Dec 15, 2025 Started: Dec 9, 2016 Primary completion: Dec 8, 2027 Completion: Dec 8, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Malignant Neoplasm in the Brain and Metastatic Melanoma, this trial is ongoing. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 32 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jul 2017 · 4 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~May 2019 · 5 months · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Aug 2020 · 7 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jan 2022 · 8 months · monthly snapshot~Jan 2022 – ~Jul 2022 · 6 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Nov 2023 · 4 months · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~May 2025 · 6 months · monthly snapshot~May 2025 – ~Nov 2025 · 6 months · monthly snapshot~Nov 2025 – ~Jan 2026 · 2 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

32 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  3. May 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 27 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Suspended → Active Not Recruiting

  3. Nov 2023 — Jan 2024 [monthly]

    Suspended PHASE2

  4. Jul 2023 — Nov 2023 [monthly]

    Suspended PHASE2

  5. Apr 2023 — Jul 2023 [monthly]

    Suspended PHASE2

    Status: Active Not Recruiting → Suspended

  6. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  7. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jan 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  9. May 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  10. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  11. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  12. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  13. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  14. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  15. Jan 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  16. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  17. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  18. Dec 2018 — May 2019 [monthly]

    Recruiting PHASE2

  19. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  20. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  21. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  22. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  23. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  24. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  25. Mar 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  26. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  27. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations